title: Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.
authors: Aya
authors: A
authors: Kuwabara
authors: Anna
authors: A
authors: Babb
authors: Amr
authors: A
authors: Ibrahim
authors: Dragana
authors: D
authors: Milojkovic
authors: Jane
authors: J
authors: Apperley
authors: Marco
authors: M
authors: Bua
authors: Alistair
authors: A
authors: Reid
authors: Letizia
authors: L
authors: Foroni
authors: Katayoun
authors: K
authors: Rezvani
authors: John
authors: J
authors: Goldman
authors: David
authors: D
authors: Marin
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic; D011743:Pyrimidines / Q000627:therapeutic use*; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate